Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | REPRINT: EV and pembrolizumab in collecting duct and renal medullary carcinoma

Giuseppe Procopio • 25 Oct 2026
ESMO 2026
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Enfortumab vedotin Pembrolizumab
REPRINT

Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, preliminary first-stage results from the Phase II REPRINT trial (NCT06302569), which evaluated enfortumab vedotin (EV) plus pembrolizumab in patients with rare, aggressive collecting duct carcinoma and renal medullary carcinoma. Antitumor activity was observed, with responses seen in a renal medullary carcinoma subtype and none in collecting duct carcinoma, and no severe adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Procopio

MeetUro 31: radiomics for PFS in metastatic clear cell renal cell carcinoma
1:13
MeetUro 31: radiomics for PFS in metastatic clear cell renal cell carcinoma
Giuseppe Procopio • 25 Oct 2026
Further molecular profiling of patients with CDC and RMC in the REPRINT trial
0:40
Further molecular profiling of patients with CDC and RMC in the REPRINT trial
Giuseppe Procopio • 25 Oct 2026
The emerging role of PARP inhibitors in prostate cancer
4:02
The emerging role of PARP inhibitors in prostate cancer
Giuseppe Procopio • 12 Feb 2021
CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC
3:24
CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC
Giuseppe Procopio • 12 Feb 2021

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals